Litcius/Paper detail

Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists

Johannes F.E. Mann, Marcel H.A. Muskiet

2021Kidney International22 citationsDOI

Topics & Concepts

MedicineType 2 diabetesDiabetes mellitusIncretinInternal medicineGlycated hemoglobinInsulin resistanceLixisenatideExenatideIntensive care medicineEndocrinologyDiabetes Treatment and ManagementPharmacology and Obesity TreatmentMetabolism, Diabetes, and Cancer
Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists | Litcius